Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer

Gynecologic Oncology

Volumn 109, Issue 3, 2008, Pages 359-363

  Lee, Hyo Pyo ^a   Seo, Sang Soo ^b   Ryu, Sang Young ^c   Kim, Jong Hyeok ^d   Bang, Yung Jue ^a   Park, Sang Yoon ^b   Nam, Joo Hyun ^e   Kang, Soon Beom ^a   Lee, Kyung Hee ^c   Song, Yong Sang ^a  

^a Seoul National University Hospital   (South Korea)

^b National Cancer Center   (South Korea)

^c Korea Cancer Center Hospital   (South Korea)

^d Asan Medical Center   (South Korea)

^e NONE

Author keywords

CKD 602; Ovarian cancer; Recurrent; Topoisomerase I

Indexed keywords

BELOTECAN; CA 125 ANTIGEN; CAMPTOTHECIN DERIVATIVE; PLATINUM;

ADULT; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS;

EID: 44449179985     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.11.023     Document Type: Article

References (32)

1. Seiden M.V., Swenerton K.D., Matulonis U., et al. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 86 (2002) 302-310
2. Huober J., Meyer A., Wagner U., and Wallwiener D. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. J Cancer Res Clin Oncol 128 (2002) 153-160
3. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 (1996) 1-6
4. Piccart M.J., Bertelsen K., Stuart G., et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 13 Suppl 2 (2003) 144-148
5. American Cancer Society. Trends in five-year survival rates by race and year of diagnosis, 1974-1996. Cancer Fact Fig (2001) 18-19
6. Rose P.G., Gordon N.H., Fusco N., et al. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. Gynecol Oncol 78 (2000) 228-234
7. Lee J.H., Lee J.M., Lim K.H., et al. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative. Ann N Y Acad Sci 922 (2000) 324-325
8. Rustin G.J., Nelstrop A.E., McClean P., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14 (1996) 1545-1551
9. Chang M.N., Therneau T.M., Wieand H.S., and Cha S.S. Designs for group sequential phase II clinical trials. Biometrics 43 (1987) 865-874
10. Bookman M.A., Malmstrom H., Bolis G., et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16 (1998) 3345-3352
11. Bridgewater J.A., Nelstrop A.E., Rustin G.J., Gore M.E., McGuire W.P., and Hoskins W.J. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 17 (1999) 501-508
12. Kudelka A.P., Tresukosol D., Edwards C.L., et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14 (1996) 1552-1557
13. Benedet J.L., Bender H., Jones III H., Ngan H.Y., and Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70 (2000) 209-262
14. Fennelly D., Aghajanian C., Shapiro F., et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15 (1997) 187-192
15. Kavanagh J., Tresukosol D., Edwards C., et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 13 (1995) 1584-1588
16. Kavanagh J.J., Kudelka A.P., de Leon C.G., et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 2 (1996) 837-842
17. McGuire W.P., Blessing J.A., Bookman M.A., Lentz S.S., and Dunton C.J. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 18 (2000) 1062-1067
18. Muggia F.M., Hainsworth J.D., Jeffers S., et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15 (1997) 987-993
19. Rose P.G., Blessing J.A., Mayer A.R., and Homesley H.D. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 16 (1998) 405-410
20. Rowinsky E.K., Grochow L.B., Hendricks C.B., et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10 (1992) 647-656
21. Shapiro J.D., Millward M.J., Rischin D., et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63 (1996) 89-93
22. Tresukosol D., Kudelka A.P., Gonzales de Leon C., et al. Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer. Eur J Gynaecol Oncol 17 (1996) 188-191
23. Bhoola S.M., Coleman R.L., Herzog T., et al. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol 95 (2004) 564-569
24. De Placido S., Scambia G., Di Vagno G., et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 22 (2004) 2635-2642
25. Gore M., ten Bokkel Huinink W., Carmichael J., et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 19 (2001) 1893-1900
26. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., and Belinson J. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol Oncol 79 (2000) 116-119
27. Swisher E.M., Mutch D.G., Rader J.S., Elbendary A., and Herzog T.J. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 66 (1997) 480-486
28. Creemers G.J., Bolis G., Gore M., et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 14 (1996) 3056-3061
29. Chen A.Y., Yu C., Potmesil M., Wall M.E., Wani M.C., and Liu L.F. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51 (1991) 6039-6044
30. Sugiyama T., Nishida T., Komai K., Nishimura H., Yakushiji M., and Nishimura H. Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer. Int J Gynaecol Obstet 54 (1996) 251-256
31. Rustin G.J., Bast Jr. R.C., Kelloff G.J., et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 10 (2004) 3919-3926
32. Rustin G.J., Nelstrop A.E., Bentzen S.M., Bond S.J., and McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 18 (2000) 1733-1739